Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

71.10 USD -1.29 (-1.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Sarepta Therapeutics

Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors 
From Business Wire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
From GlobeNewswire News Releases
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
From GlobeNewswire News Releases
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
From GlobeNewswire News Releases
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial P
From GlobeNewswire News Releases
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
From GlobeNewswire News Releases
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
From GlobeNewswire News Releases
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
From GlobeNewswire News Releases
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
From GlobeNewswire News Releases
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administrat
From GlobeNewswire News Releases
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
From GlobeNewswire News Releases
AavantiBio Bolsters Leadership Team with Appointment of Ty Howton as Chief Operating Officer and General Counsel
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel.... 
From Business Wire News Releases
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/08/2021 -- Certain directors of Sarepta Therapeutics, Inc are under investigation concerning potential breaches of fiduciary duties. 
From SBWire - Latest Press Releases
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.